4.5 Article

A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma

Journal

BONE MARROW TRANSPLANTATION
Volume 50, Issue 11, Pages 1416-1423

Publisher

SPRINGERNATURE
DOI: 10.1038/bmt.2015.177

Keywords

-

Funding

  1. Public Health Service from the National Cancer Institute (NCI) [U24-CA076518]
  2. National Heart, Lung and Blood Institute (NHLBI)
  3. National Institute of Allergy and Infectious Diseases (NIAID)
  4. NHLBI [5U10HL069294]
  5. NCI
  6. Health Resources and Services Administration (HRSA/DHHS) [HHSH250201200016C]
  7. Office of Naval Research [N00014-12-1-0142, N00014-13-1-0039]
  8. Actinium Pharmaceuticals
  9. Allos Therapeutics, Inc.
  10. Amgen, Inc.
  11. Ariad
  12. Be the Match Foundation
  13. Blue Cross and Blue Shield Association
  14. Celgene Corporation
  15. Chimerix, Inc.
  16. Fred Hutchinson Cancer Research Center
  17. Fresenius-Biotech North America, Inc.
  18. Gamida Cell Teva Joint Venture Ltd.
  19. Genentech, Inc.
  20. Gentium SpA
  21. Genzyme Corporation
  22. GlaxoSmithKline
  23. Health Research, Inc.
  24. Roswell Park Cancer Institute
  25. HistoGenetics, Inc.
  26. Incyte Corporation
  27. Jeff Gordon Children's Foundation
  28. Kiadis Pharma
  29. Leukemia & Lymphoma Society
  30. Medac GmbH
  31. Medical College of Wisconsin
  32. Merck Co, Inc.
  33. Millennium: The Takeda Oncology Co.
  34. Milliman USA, Inc.
  35. Miltenyi Biotec, Inc.
  36. National Marrow Donor Program
  37. Onyx Pharmaceuticals
  38. Optum Healthcare Solutions, Inc.
  39. Osiris Therapeutics, Inc.
  40. Otsuka America Pharmaceutical, Inc.
  41. Perkin Elmer, Inc.
  42. Remedy Informatics
  43. Sanofi US
  44. Seattle Genetics
  45. Sigma-Tau Pharmaceuticals
  46. Soligenix, Inc.
  47. St Baldrick's Foundation
  48. StemCyte, A Global Cord Blood Therapeutics Co.
  49. Stemsoft Software, Inc.
  50. Swedish Orphan Biovitrum
  51. Tarix Pharmaceuticals
  52. TerumoBCT
  53. Teva Neuroscience, Inc.
  54. THERAKOS, Inc.
  55. University of Minnesota
  56. University of Utah
  57. Wellpoint, Inc.

Ask authors/readers for more resources

Autologous hematopoietic cell transplantation (AutoHCT) is a potentially curative treatment modality for relapsed/ refractory Hodgkin lymphoma (HL). However, no large studies have evaluated pretransplant factors predictive of outcomes of AutoHCT in children, adolescents and young adults (CAYA, age < 30 years). In a retrospective study, we analyzed 606 CAYA patients (median age 23 years) with relapsed/refractory HL who underwent AutoHCT between 1995 and 2010. The probabilities of PFS at 1, 5 and 10 years were 66% (95% confidence interval (CI): 62-70), 52% (95% CI: 48-57) and 47% (95% CI: 42-51), respectively. Multivariate analysis for PFS demonstrated that at the time of AutoHCT patients with Karnofsky/Lansky score >= 90, no extranodal involvement and chemosensitive disease had significantly improved PFS. Patients with time from diagnosis to first relapse of < 1 year had a significantly inferior PFS. A prognostic model for PFS was developed that stratified patients into low-, intermediate-and high-risk groups, predicting for 5-year PFS probabilities of 72% (95% CI: 64-80), 53% (95% CI: 47-59) and 23% (95% CI: 9-36), respectively. This large study identifies a group of CAYA patients with relapsed/refractory HL who are at high risk of progression after AutoHCT. Such patients should be targeted for novel therapeutic and/or maintenance approaches post-AutoHCT.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available